Volume 9 Number 3 March 2012 - Oncology Practice Digital Network

More documents

Recommendations

Info

March 2012 VOLUME 9, NUMBER 3 contents IMNG, LLC 60B Columbia Road Morristown, NJ 07960 973.290.8200 tel ● 631.424.8905 fax Alan Imhoff, President and Publisher Mary Jo Dales, Editorial Director Reneé Matthews, Managing Editor Elizabeth Mechcatie, Matt Stenger, Contributing Writers Virginia Ingram-Wells, Copy Editor Peter Murphy, Stuart Williams, National Accounts Managers Yvonne Evans, Production Manager Devin Gregorie, National Accounts Manager—Oncology Projects FROM THE EDITOR 75 Assessing for physiologic not chronologic age in the elderly David H. Henry, MD, FACP COMMENTARY 81 Don’t shortchange older cancer patients Stuart M. Lichtman, MD, FACP 83 Vemurafenib’s companion assay refines use of the targeted therapy John M. Kirkwood, MD COMMUNITY TRANSLATIONS 85 Vemurafenib in melanoma with the BRAF V600E mutation Edited by Jame Abraham, MD; report prepared by Matt Stenger, MS REVIEW 87 Bench-to-bedside translation of targeted therapies in multiple myeloma Kenneth C. Anderson, MD 94 Therapeutic optimization of aromatase inhibitor–associated arthralgia: etiology, onset, resolution, and symptom management in early breast cancer Cheryl Jones, MD, James Gilmore, PharmD, Mansoor Saleh, MD, Bruce Feinberg, DO, Michelle Kissner, RPh, PharmD, and Stacey J. Simmons, MD LETTERS Community Oncology (ISSN 1548-5315) is published monthly by IMNG, LLC, 60B Columbia Road, Morristown, NJ 07960. Periodicals postage paid at Morristown, NJ, and additional mailing offices. Change of Address Postmaster: send address changes to Community Oncology, Circulation, IMNG, LLC, 60B Columbia Road, Morristown, NJ 07960. Recipient: to change your address, contact b.cavallaro@elsevier.com, telephone: 973.290.8253, or mail to Community Oncology, Circulation, IMNG, LLC, 60B Columbia Road, Morristown, NJ 07960. Case Letters 102 Extramedullary BCR-ABL positive T-lymphoblastic leukemia in a patient with chronic myelogenous leukemia Mylene Go, MD, Le Wang, MD, PhD, JinMing Song, MD, and Rene Rubin, MD 106 Decitabine–induced acute lung injury Monica Marwaha, MD, and Huzefa Bahrain, DO FEATURES Survivorship 108 Creating partnerships for survival Mark Sborov, MD, and Michele O’Brien, RN, MSN, ACNS-BC, BA Practical Biostatistics 110 Moving up in the world: screening for lung cancer David L. Streiner, PhD, CPsych, and Geoffrey R. Norman, PhD Fellows’ Corner 112 How I treat ...ASH David Askin, DO, and Jerry George, DO Volume 9/Number 3 March 2012 COMMUNITY ONCOLOGY A7
March 2012 VOLUME 9, NUMBER 3 Information for Authors and Advertisers Aims and Scope COMMUNITY ONCOLOGY is an independent journal that publishes peerreviewed research, review articles and commentary on all aspects of clinical oncology practice. Article types include original clinical studies in practice-based settings, state-of-the-art review papers, peer viewpoints, commentaries, and letters to the editor. For a full and complete guide for authors, go to ees.elsevier.com/co/ For further information, contact the Managing Editor, Renée Matthews, at 240-221-2461 or e-mail, renee.matthews@elsevier.com. Correspondence For general, noneditorial enquiries, write to COMMUNITY ONCOLOGY, 60B Columbia Road, Morristown, NJ 07960; tel: 973-290-8200; fax: 973-290-8250. Letters to the Editor should be addressed to the Editor-in-Chief, David H. Henry, MD, FACP, e-mail: c.oncology@elsevier.com. Advertising For information regarding advertising rates, contact Peter Murphy (tel: 201-529-4020; e-mail: pmurphy@braveheart-group.com) or Stuart Williams (tel: 201-529-4004; e-mail: swilliams@braveheart-group.com); for information regarding supplements and projects, contact Devin Gregorie (tel: 516-381-8613; e-mail: d.gregorie@elsevier.com). CME Supplements For information on CME supplements to COMMUNITY ONCOLOGY, contact Sylvia Reitman of Global Academy for Medical Education, LLC, at e-mail: s.reitman@globalacademycme.com. Annual Subscription Rates For 12 issues (in US$): Individual $380, Canada $413, International $413; Institutional $380, Canada $413, International, $413; Single copy $45. For further information regarding subscriptions, contact Barbara Cavallaro, e-mail: b.cavallaro@elsevier.com COMMUNITY ONCOLOGY (ISSN 1548-5315) is published monthly by International Medical News Group, LLC, 60B Columbia Road, Morristown, NJ 07960. Copyright Copyright © 2012 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the Publisher. Disclaimer Discussions, views, opinions, and recommendations as to medical procedures, products, choice of drugs, and drug dosages are the responsibility of the authors or advertisers. No responsibility is assumed by the Publisher, Editor, or Editorial Board for any injury and/or damage to persons or property as a matter of product liability, negligence, or otherwise or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, independent verification of diagnoses and drug dosages should be made. Advertiser and advertising agency recognize, accept, and assume liability for all content (including text, representations, illustrations, opinions, and facts) of advertisements printed and also assume responsibility for any claims made against the Publisher arising from or related to such advertisements. In the event that legal action or a claim is made against the Publisher arising from or related to such advertisements, advertiser and advertising agency agree to fully defend, indemnify, and hold harmless the Publisher and to pay any judgment, expenses, and legal fees incurred by the Publisher as a result of said legal action or claim. The Publisher reserves the right to reject any advertising that he feels is not in keeping with the publication’s standards. The Publisher is not liable for delays in delivery and/or nondelivery in the event of Act of God, action by any government or quasigovernmental entity, fire, flood, insurrection, riot, explosion, embargo, strikes (whether legal or illegal), labor or material shortage, transportation interruption of any kind, work slowdown, or any condition beyond the control of the Publisher that affects production or delivery in any manner. This journal is printed on paper meeting the requirements of ANSI/ NISO Z39.48-1992 (Permanence of Paper) effective with Volume 1, Issue 1, 2004. Community Oncology is indexed by EMBASE and the Cumulative Index to Nursing and Allied Health Literature (CINAHL) A8 COMMUNITY ONCOLOGY March 2012 www.CommunityOncology.net
Page 1 and 2: Volume 9 ● Number 3 ● March 201
Page 3: March 2012 VOLUME 9, NUMBER 3 Edito
Page 7 and 8: Commentary Don’t shortchange olde
Page 9 and 10: Commentary Vemurafenib’s companio
Page 11 and 12: Community Translations Edited by Ja
Page 13 and 14: Review Bench-to-bedside translation
Page 15 and 16: Anderson Specifically, we have deve
Page 17 and 18: Anderson ating whether high-dose ch
Page 19 and 20: Anderson diates activity via downre
Page 21 and 22: Jones et al creased efficacy and in
Page 23 and 24: Jones et al Estrogen deprivation is
Page 25 and 26: Jones et al (eg, VSL#3), bisphospho
Page 27 and 28: Jones et al 39. Mao JJ, Su HI, Feng
Page 29 and 30: Case Letter FIGURE 1 Peripheral blo
Page 31 and 32: Case Letter CHR tends to be short-l
Page 33 and 34: Case Letter the treatment modality
Page 35 and 36: Survivorship A survivor speaks My n
Page 37 and 38: Practical Biostatistics less dollar

Volume 9 Number 3 March 2012 - Oncology Practice Digital Network

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?